Presentation is loading. Please wait.

Presentation is loading. Please wait.

VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus.

Published byYohanes Darmadi Modified over 5 years ago

Similar presentations

Presentation on theme: "VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus."— Presentation transcript:

1 VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus.
VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus. (A) Summary of genetic experiments: Deletion of VEGFR-2 from all cells results in specific injury to the glomerular microvasculature that resembles the glomerular endothelial injury observed in mice with specific deletion of the VEGF ligand from podocytes. Deletion of VEGFR-2 from podocytes does not cause significant glomerular disease. Together, these results do not support a major role for autocrine VEGF signaling through VEGFR-2 in the glomerulus. (B) VEGF is produced by the podocytes and functions through a paracrine signaling loop to act on VEGFR-2 expressed by glomerular endothelial cells. Karen Sison et al. JASN 2010;21: ©2010 by American Society of Nephrology

Download ppt "VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus."

Similar presentations

VEGF gene expression in HPMVEC and VEGF protein levels in CM

VEGF gene expression in HPMVEC and VEGF protein levels in CM
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Volume 81, Issue 1, Pages 5-6 (January 2012)

Volume 81, Issue 1, Pages 5-6 (January 2012)
Renal manifestations in Fabry disease and therapeutic options

Renal manifestations in Fabry disease and therapeutic options
Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.
PDE5A is expressed by podocytes.

PDE5A is expressed by podocytes.
Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific PPAR-γ KO mice. Sildenafil does.

Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific PPAR-γ KO mice. Sildenafil does.
Downregulation of TRPC6 expression by sildenafil leads to reduced TRPC6–mediated Ca2+ influx into the podocyte. Downregulation of TRPC6 expression by sildenafil.

Downregulation of TRPC6 expression by sildenafil leads to reduced TRPC6–mediated Ca2+ influx into the podocyte. Downregulation of TRPC6 expression by sildenafil.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Five independent associations were identified after stepwise association analysis within the MHC region at the discovery stage. Five independent associations.

Five independent associations were identified after stepwise association analysis within the MHC region at the discovery stage. Five independent associations.
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.

Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.
Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.

Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.
Antibody–mediated C5 inhibition in hepatocyte-Cfh−/− mice during accelerated serum NTN. (A) Hematuria, (B) serum urea, (C) red cell fragments, (D) glomerular.

Antibody–mediated C5 inhibition in hepatocyte-Cfh−/− mice during accelerated serum NTN. (A) Hematuria, (B) serum urea, (C) red cell fragments, (D) glomerular.
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Loss of glomerular ESL contributes to increased glomerular albumin sieving coefficient, and modification of ESL improves glomerular albumin sieving coefficient,

Loss of glomerular ESL contributes to increased glomerular albumin sieving coefficient, and modification of ESL improves glomerular albumin sieving coefficient,
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Figure 2 Three distinct mechanisms of activation of

Figure 2 Three distinct mechanisms of activation of

Similar presentations

Ads by Google